Highest-materiality recent filing
Medifast appoints Nicholas Johnson as CEO; Dan Chard becomes non-executive Chairman
Nicholas Johnson, 46, becomes CEO effective June 1, 2026; Dan Chard transitions to non-executive Chairman.
Medifast Q1 revenue $76M, down 34% YoY; net loss $2.1M; guides Q2 revenue $60-80M
Revenue fell 34.3% to $76.0M; net loss widened to $2.1M ($0.19 EPS) from $0.8M loss.
Medifast (MED) entered a Cooperation Agreement with Steamboat Capital Partners (beneficial owner >5%) on March 19, 2026.
Medifast Q4 revenue falls 37% to $75.1M; net loss $18.1M, guides FY26 rev $270-300M
Revenue $75.1M, down 36.9% YoY; active earning coaches down 40.6% to 16,100.
Medifast Q3 revenue down 36% to $89.4M; net loss $2.3M; coaches drop 35%
Revenue $89.4M vs $140.2M YoY; net loss $0.21 per diluted share vs $0.10 income.
Medifast Q2 revenue falls 37.4% to $105.6M; active coaches down 33%; Q3 guidance weak
Revenue $105.6M, down 37.4% YoY; active OPTA VIA coaches 22,800 (-32.7% YoY); diluted EPS $0.22 (includes $2.0M net LifeMD gain).
Medifast Q1 2025: revenue down 34% to $115.7M, net loss $0.8M; Q2 guidance weak
Revenue fell 33.8% to $115.7M; active earning coaches down 32.8% to 25,400.
Medifast Q4 revenue down 38% to $119M; EPS $0.07; guides Q1 loss
Q4 revenue $119M (-37.7% YoY); active earning coaches 27,100 (-34.1% YoY).
On May 20, 2026, the Board appointed Nicholas Johnson, age 46, to serve as Chief Executive Officer of the Company, effective June 1, 2026.
Max materiality 0.90 · Median 0.78 · Most common event earnings